The ability to serve the cardiovascular market with state-of-the-art medical technology begins with solid, experienced leadership. Our Board of Directors and Executive Leadership are dedicated to collaborating with physicians to help get their patients back to what matters.
Chairman, President & CEO
Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer.
From 2013 until 2019, Mr. Ward served as a Managing Director at SightLine Partners. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc., and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes business, from February 2002 to May 2004, and was President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 4, 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc., from September 2010 to March 2015.
Vice President & General Manager, Coronary Sales
Mr. Beverly rejoined CSI in May 2021. He is responsible for leading CSI’s Coronary Franchise. Prior to his return to CSI, Mr. Beverly served as the Head of US Sales for Abbott within the Rapid Diagnostics Division. Mr. Beverly originally joined CSI in 2015 where he held several leadership roles including Area Vice President. Mr. Beverly brings over 20 years of Healthcare experience to his role at CSI.
Chief Medical Officer
Dr. Egeland joined CSI in November of 2017. He has responsibilities providing global leadership, medical counsel and guidance to the organization on matters related to cardiovascular medicine, product and technology development, medical education, market development, quality assurance, clinical program design, clinical data analysis, regulatory affairs, and business development. Prior to joining CSI, Dr. Egeland held roles in marketing, medical affairs, and business development at Medtronic. Before this, he trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital, and received an MD with honors from Harvard Medical School. Dr. Egeland also holds a PhD in biochemistry and engineering from the University of Oxford, where he also completed a MBA as a Rhodes Scholar.
Vice President, Manufacturing & Operations
Mr. Hastings joined CSI as Vice President of Manufacturing and Operations in October of 2017. He is responsible for global Manufacturing, Operations, Supply Chain and Distribution. Prior to joining CSI, Mr. Hastings held several leadership roles at Abbott Laboratories (formerly St. Jude Medical), most recently as Sr. Site Director, Operations. Mr. Hastings served as Director of Engineering for American Medical Systems prior to his role with Abbott.
Vice President & General Manager, Peripheral Sales
Mr. Muscari joined CSI in July 2015. He is responsible for leading the CSI’s Peripheral Franchise. He brings 20 years of medical device experience to the organization. Mr. Muscari started his career in the United States Marine Corps, where he held multiple leadership roles. Following his time in the service, he successfully led multiple sales and leadership teams at US Surgical, Intuitive Surgical and CSI.
Vice President, Investor Relations & Corporate Communications
Mr. Nielsen joined CSI in March 2014. He has over 25 years of investment experience. Before joining CSI, Mr. Nielsen served as Director of Investor Relations at Xcel Energy and prior served as Director of Finance at Regis Corporation. Mr. Nielsen began his career as a securities analyst, covering a variety of high growth companies for Minneapolis-based investment banks. He served as a member of the National Investor Relations Institute Twin Cities board of directors from 2007 to 2019.
Chief Financial Officer
Mr. Points joined CSI in September 2007 as Corporate Controller, became Senior Director and Controller in July 2013, Corporate Controller and Treasurer in January 2015, Vice President, Corporate Controller and Treasurer in May 2017 and was promoted to Chief Financial Officer in February 2018. From July 2005 to September 2007, Mr. Points was Assistant Controller at Empi, a manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. From January 1998 to July 2005, Mr. Points held various leadership positions at CliftonLarsonAllen, a national public accounting firm. Mr. Points also serves as a member of the Board of Directors for The Phoenix Residence, Inc.
Chief Human Resources Officer
Mr. Rempe joined CSI in May 2019. He provides leadership in talent acquisition, organization development and effectiveness and talent development as we continue to scale our business. Mr. Rempe has over 20 years of human resources experience, most recently at Smiths Medical as Senior Vice President of Global Human Resources and prior, serving as Vice President of Global Talent Management at Boston Scientific. Mr. Rempe serves as a member of the Board of Trustees for The Works, a non-profit organization whose mission is to inspire the next generation of engineers, innovators and creative problem solvers.
Chief Operating Officer
Ms. Robb joined CSI as Chief Operating Officer in January 2018. Ms. Robb brings more than 30 years of medical device leadership to the company. Prior to CSI, she held several positions at Medtronic, most recently as Vice President and General Manager of the Heart Valve Therapies Business, including the transcatheter aortic valve business. In previous roles, Ms. Robb held leadership positions in Medtronic’s Coronary, Peripheral, and Cardiac Rhythm and Heart Failure businesses.
General Counsel & Corporate Secretary
Mr. Rosenstein joined CSI in September 2014 as Corporate Legal and Compliance Counsel, became Corporate Secretary in November 2014, and was promoted to General Counsel in March 2015. From October 2005 to September 2014, Mr. Rosenstein was an attorney at Fredrikson & Byron, P.A., in Minneapolis. From 1998 to September 2005, he was an attorney practicing in New York City.
Chief Compliance Officer
Ms. Sedo joined CSI in June 2016. As Chief Compliance Officer, she is responsible for managing the company’s ethics and compliance program, including implementation of a Corporate Integrity Agreement. Ms. Sedo has over 25 years of experience as a lawyer and compliance professional, including being a partner at Dorsey & Whitney, LLP and as an in-house attorney and Deputy Compliance Officer at Medtronic. Ms. Sedo has worked exclusively in the medical device industry since 2005.
Vice President & General Manager, International
Mr. Volker joined CSI in August 2014 as Vice President of Corporate Development and Healthcare Economics & Reimbursement and was promoted to General Manager of International in 2017. Prior to CSI, Mr. Volker held senior leadership positions at St. Jude Medical including responsibilities for Corporate Development, Health Economics & Reimbursement, Strategic Market Research and Human Resources. He began his career working in investment banking and venture capital. Mr. Volker received a Bachelor of Arts in Economics and Management from St. John’s University and an MBA in Finance from The Wharton School at the University of Pennsylvania.
Vice President, Corporate Development & Intellectual Property
Mr. Whitescarver joined CSI as Vice President of Corporate Development and Intellectual Property in June 2017. Mr. Whitescarver brings more than 15 years of global leadership experience in the biomedical sector to the company, including senior leadership positions at Medtronic. Prior to this experience, Mr. Whitescarver led global teams at a Fortune 500 technology company and practiced law with a leading Wall Street firm.
Chairman, President & CEO
Mr. Ward has been a member of CSI’s Board of Directors since 2013 and has served as Chairman since November 2014.
Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer.
From 2013 until 2019, Mr. Ward served as a Managing Director at SightLine Partners. From 1981 to 2010, Mr. Ward was employed by Medtronic, Inc. and held a number of senior leadership positions. Mr. Ward was Senior Vice President and President of Medtronic’s CardioVascular business from May 2007 to November 2010. Prior to that he was Senior Vice President and President of Medtronic’s Vascular business from May 2004 to May 2007, Senior Vice President and President of Medtronic’s Neurological and Diabetes business, from February 2002 to May 2004, and was President of Medtronic’s Neurological business from January 2000 to January 2002. He was Vice President and General Manager of Medtronic’s Drug Delivery business from 1995 to 2000. Prior to that, Mr. Ward led Medtronic’s Neurological Ventures in the successful development of new therapies. Mr. Ward serves on the boards of several private companies. Until April 4, 2016, Mr. Ward was the Chairman of the Board of Creganna Medical. Mr. Ward served as a member of the Board of Surmodics, Inc., from September 2010 to March 2015.
Ms. Aronson has been a member of CSI’s Board of Directors since February 2017.
Ms. Aronson served as Executive Vice President of Strategic Planning at Ecolab, Inc. from November 2015 to April 2016, and previously served as Ecolab’s Executive Vice President and President-Global Healthcare, from September 2012 to November 2015. From 2010 to 2012, Ms. Aronson served as Senior Vice President and President, North America, of Hill-Rom Holdings, Inc. Before joining Hill-Rom, she served as Senior Vice President at Medtronic, Inc., from March 2008 to November 2009, and in various other domestic and international management positions with Medtronic, since 1991. She is also a director of CONMED Corporation and Beta Bionics, Inc., and previously served as a director of Methode Electronics from 2016 to 2019, Hutchinson Technology from 2010 to 2016, when it was acquired, and Clinical Innovations from 2017 to 2020, when it was acquired.
Mr. Brown has been a member of CSI’s Board of Directors since February 2009 and was appointed as our Lead Independent Director in August 2016.
Mr. Brown currently serves as Operating Partner at Five Arrows Capital Partners, of the U.S. private equity business of the Rothschild Group. Mr. Brown was previously a Partner at Health Evolution Partners from 2010 to 2016, Managing Director at TPG Biotech from 2007 to 2009 and a Managing Director and co-founder of Healthcare Investment Partners, a private equity fund focused on healthcare investments, from 2004 to 2007. Before Healthcare Investment Partners, Mr. Brown was a Managing Director in the healthcare group of Credit Suisse Group where he led the firm’s West Coast healthcare effort and was one of the senior partners responsible for the firm’s global life sciences practice. Mr. Brown previously served on the boards of Freedom Innovations, LLC and Prolacta Biosciences, Inc., both private companies. Mr. Brown previously served on the public company boards of Angiotech Pharmaceuticals, Inc., from January 2007 to June 2011, Oculus Innovative Sciences, Inc., from September 2005 to June 2008, and Replidyne, Inc., from May 2007 to February 2009, as well as several private company boards.
Dr. Cohn has been a member of CSI’s Board of Directors since February 2015.
Dr. Cohn is a Vice President of Medical Devices and Director of the Center for Device Innovation at Johnson & Johnson. He is also a Cardiothoracic Surgeon and a professor of Surgery at Baylor College of Medicine. Dr. Cohn is the Chief Medical Officer of BiVACOR USA, a privately-held medical device company. He is also a venture partner with Santé Ventures, an early stage life science fund in Austin, Texas. Dr. Cohn has more than 90 U.S. patents granted or pending for medical device development.
Dr. Jain has been a member of CSI’s Board of Directors since January 2021.
Dr. Jain is currently President and Chief Executive Officer of SCAN Group and Health Plan. From 2014 to 2020, he held several increasing leadership positions at CareMore & Aspire Health, including President and Chief Executive Officer. From 2012 to 2014, Dr. Jain was Chief Medical and Information Officer at Merck & Co. From 2009 to 2011, he worked in several leadership roles at the US Department of Health and Human Services, including as senior advisor to the administrator of the Centers for Medicare & Medicaid Services.
Dr. Jain is an adjunct professor of medicine at the Stanford University School of Medicine and a contributor to Forbes. He serves as a member of the Board of Directors of America’s Health Insurance Plans (AHIP), Abode Hospice, and the Make-A-Wish Foundation. He is also an Aspen Institute Health Innovator’s Fellow.
Dr. Jain graduated magna cum laude from Harvard College with a BA in government and continued on to earn his MD from Harvard Medical School and MBA from Harvard Business School.
Mr. Lawlor has been a member of CSI’s Board of Directors since February 2009.
Mr. Lawlor is the Managing Partner of HealthCare Ventures, LLC, where he was a Managing Director from 2000 to 2007. Mr. Lawlor is also the Chief Operating Officer of Leap Therapeutics. Mr. Lawlor was previously Chief Operating Officer of LeukoSite, Inc. and has also served as a management consultant with KPMG Peat Marwick. Mr. Lawlor serves on the Board of Directors of Catalyst Biosciences, Inc., as well as several private companies. He served on the Board of Directors of Human Genome Sciences, Inc., from March 2004 to August 2012, and the Board of Directors of Replidyne, Inc., from March 2002 to February 2009.
Mr. Paulsen has been a member of CSI’s Board of Directors since July 2019.
From 2009 to 2019, he represented Minnesota’s Third Congressional District in the United States House of Representatives. During his tenure, Mr. Paulsen was a leading member on the House Ways and Means Committee, the House’s chief tax-writing body with broad jurisdiction over healthcare, economic and trade policy. Mr. Paulsen was also Chairman of Congress’ Joint Economic Committee, a unique House-Senate panel tasked with working alongside the President’s Council of Economic Advisors and the Federal Reserve Board to identify and address macroeconomic trends. Mr. Paulsen was co-chair of the bipartisan House Medical Technology Caucus, as well. Prior to his service in Congress, Mr. Paulsen was a member of the Minnesota State Legislature, where he served as House Majority Leader. Mr. Paulsen has over 16 years of business experience, including working as a business analyst at Target Corporation.
Mr. Stenbeck has been a member of CSI’s Board of Directors since November 2019.
A retired partner of Ernst & Young LLP (EY), Mr. Stenbeck brings 36 years of experience serving Fortune 500, midcap, and small cap public company audit clients in the medical device, retail, consumer products, distribution, airline and media and entertainment industries. Clients served as coordinating partner include several public medical device companies with significant international operations. Mr. Stenbeck also served for three years as a Professional Practice partner at EY consulting on technical accounting matters, and currently serves as a board member of Catholic Charities of St. Paul and Minneapolis.
Mr. Womack has served as a member of CSI’s Board of Directors since August 2020.
Mr. Womack is currently the Vice President for Diversity and Inclusion at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to this role, he served for 30 years as a consulting professional, primarily in the healthcare industry. His more recent roles include leading the federal healthcare consulting practices for Deloitte, LLP and BearingPoint, Inc. From 2007 until 2019 he served as a board member of the Children’s Inn at the National Institute of Health, including two years as Chairman of the Board.